Glenmark Pharmaceuticals and SaNOtize Announce Peer-Reviewed Publication of Its Phase 3 Clinical Trials of SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in The Lancet Journal

The Lancet Regional Health Southeast Asia Releases Successful Phase 3 Clinical Trial Results of Nitric Oxide Nasal Spray.

Phase 3 trial of nitric oxide nasal spray administered to adult patients with COVID-19 in India achieved key endpoints and demonstrated viral load reductions of 94% in 24 hours and 99% in 48 hours.

Nitric oxide nasal spray was safe and well tolerated in COVID-19 patients.

Following positive results and regional approvals, Glenmark launched this nasal spray in India under the FabiSpray® brand and Singapore and hong kong under the brand name VirX™.

Mumbai, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) – A high-impact, peer-reviewed journal has published the successful Phase 3 clinical trial results of the SaNOtize Nitric Oxide Nasal Spray (NONS) study titled: ‘SAccelerated Clearance of ARS-CoV-2 Using a Novel Nitric Oxide Nasal Spray (NONS) Treatment: A Randomized Trial”.

https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext

“We are delighted to publish the study of the novel Nitric Oxide Nasal Spray, which has a positive impact on people’s lives, in The Lancet review group. The robust double-blind trial demonstrated significant efficacy and safety remarkable contribution from NONS. This therapy has the potential to make a critical contribution to the management of COVID-19, with its ease of use in the current highly transmissible phase of the pandemic,” said Dr. Monika TandonSenior Vice President and Head of Clinical Development, Glenmark Pharmaceuticals Ltd.

The study demonstrated that patients who received NONS had a significant reduction in viral load within 24 hours, which was maintained for seven days of treatment. Viral load was reduced by 93.7% within 24 hours and by 99% within 48 hours of treatment with NONS. The mean change from baseline in logarithm of viral RNA load over the entire course of treatment was statistically greater with NONS than with placebo. Similar results were observed in vaccinated and unvaccinated populations. The study was conducted during delta and omicron surges. Key secondary endpoints, including clinical improvement as assessed by WHO Clinical Progression Scale score and extent/speed of virologic recovery, were demonstrated in patients using NONS. The median time to virological cure was three days in the NONS group and seven days in the placebo group after the start of treatment (four days earlier). The exploratory assessment of the proportion of immediate contacts testing positive for COVID-19 or becoming symptomatic remained almost the same in the NONS group while it increased numerically in the placebo group during treatment.

“The Phase 3 study results strongly support the safety and efficacy of NONS in the treatment of COVID-19 and its known variants,” said Gilly Regev, PhD, SaNOtize Co-founder and CEO. “Nitric oxide blocks entry into the nasal passage, kills the virus and stops its replication, which is why viral load is reduced so quickly with NONS. Viral load has been linked to infectiousness, poorer health outcomes and complications from long COVID. Evidence is accumulating that NONS represents an effective and well-tolerated antiviral therapy that significantly shortens the course of COVID-19. »

study design

The study was conducted by Glenmark on 306 vaccinated and unvaccinated adults with mildly symptomatic COVID-19 at 20 clinical sites in India. This randomized, double-blind Phase 3 clinical trial evaluated a seven-day course of NONS plus standard therapy versus placebo nasal spray plus standard therapy in patients with symptomatic COVID-19. The primary endpoint of accelerated clearance of nasal SARS-CoV-2 RNA was used to assess the efficacy of this transformational NONS in high-risk patients (unvaccinated, or aged 45, or having one or more comorbidities) after seven days of treatment . The exploratory evaluation of NONS in preventing infection in immediate contacts of these COVID-19 patients was also assessed.

NONS treatment was well tolerated, establishing a benefit of locally acting nasal therapy. None of the patients reported moderate or severe adverse effects. There were no clinically significant changes from baseline observed in methemoglobin suggesting a lack of systemic availability of nitric oxide from the nasal spray. In addition, no symptoms of nasal vasodilation or signs of systemic vasodilation were observed in either treatment.

Strategic partnership with SaNOtize

In July 2021Glenmark has entered into an exclusive long-term strategic partnership with Canadian biotech company SaNOtize, to manufacture, market and distribute its breakthrough nitric oxide nasal spray for the treatment of COVID-19 in India and other Asian markets, including Singapore, Malaysia, hong kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Burma, Sri LankaTimor-Leste and Vietnam.

Global approvals for NONS

Glenmark launched NONS under the FabiSpray® brand in February 2022after having received manufacturing and marketing approval from the Comptroller General of Medicines of India (DCGI) under the expedited approval process. NONS has already received the CE mark in Europe, which is equivalent to a marketing authorization in the case of a medical device. Under the CE mark, SaNOtize is authorized to launch NONS in the EU. NONS is also approved and sold in Singapore, hong kong, Israel, Thailand, Indonesia and Bahrain, under the name enovid™ or VirX™. Apart from IndiaNONS has also been approved globally for protection against viruses including SARS COV-2.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with operations in the specialty, generic and over-the-counter sectors. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing plants across 4 continents and operations in over 80 countries. Glenmark is ranked among the top 100 biopharmaceutical companies in the world (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the top 50 global companies in the non-patent sector (Top 50 Generics and Biosimilars Companies ranking by Sales, 2020, by Generics Bulletin/In Vivo). The company has been listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, in the Emerging Markets category (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com.

Follow us on social networks:

LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

About SaNOtize

SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, marketing the multifaceted antimicrobial properties of a nitric oxide-producing liquid. The company has developed and patented Nitric Oxide Release Solution Platform Technology (NORS) to treat and prevent topical and upper respiratory tract infections. For more information, visit www.SaNOtize.com. Follow us on social networks: LinkedIn, Twitter.

Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

SOURCEGlenmark Pharmaceuticals Ltd.

Comments are closed.